Given that aberrant cytosine methylation is a hallmark of human cancers and that DNA methylation is a stable molecular feature detectable in tissues, blood, and other bodily fluids, our study suggests that ONECUT2 gene-body DNA methylation status may serve as a valuable tool for predicting aggressive PCa features. The gene discussed is ONECUT2; the disease is cancer.